Regulatoriskt pressmeddelande

AstraZeneca presents further data showing the interconnectivity between cardiovascular and renal risks in diabetes at EASD 2018

AstraZeneca and MedImmune, its global biologics research and development arm, will present more than 50 abstracts from the Company's Cardiovascular, Renal & Metabolism (CVRM) therapy area at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany, 1-5 October 2018.

This latest research underscores AstraZeneca's expansive clinical trial programme and comprehensive approach to advancing clinical practice in the management of cardiovascular, renal and metabolic (CaReMe) diseases. Data to be presented from the Company's broad portfolio include Farxiga (dapagliflozin) and Bydureon (exenatide extended-release) in type-2 diabetes (T2D), alone and in combination with other diabetes therapies. Highlights also include data on the potential of Farxiga in type-1 diabetes (T1D) and additional pre-clinical and clinical data for MEDI0382, a potential first-in-class oxyntomodulin-like peptide for type-2 diabetes and the latest candidate in the Company's CVRM pipeline.

Ludovic Helfgott, Vice President, Cardiovascular, Renal and Metabolism at AstraZeneca, said: "Our key data at EASD will expand understanding around the persistent cardiovascular and renal risks in patients with type-2 diabetes, as well as the unmet need in type-1 diabetes, where we are at the forefront of advancing treatment for patients. We are constantly pursuing science to advance the management of cardiovascular, renal and metabolic diseases to improve patient outcomes."

New data to highlight the potential of Farxiga in T2D and interconnectivity between CV and renal diseases

Highlights include several abstracts evaluating the effects of Farxiga alone and in combination in treating T2D, and in patients with CV (including heart failure) and renal risk factors. Research into CaReMe diseases includes a recent trial on CV outcomes and mortality in people with T2D and associated comorbidities (Poster #1177). The results will illustrate the importance of identifying novel protection strategies for various T2D-related comorbidities, including heart failure and chronic kidney disease, and may have implications for investigating risk in T2D patients.

A further presentation will include 52-week results of Farxiga as an add-on therapy to Onglyza (saxagliptin) in addition to metformin, compared with insulin in patients with or without sulfonylurea therapy.

For patients with T1D, insulin is the standard therapy with no oral treatment options approved to date. The latest sub-analysis (Poster #612) of pooled data from the DEPICT (Dapagliflozin Evaluation in Patients with Inadequately Controlled Type-1 Diabetes) clinical trial programme (DEPICT-1 and DEPICT-2) features an evaluation on the effect of Farxiga in T1D patients taking adjustable insulin treatment. The analysis will look at two composite endpoints, including those determining instances of weight gain, severe hypoglycaemia and diabetic ketoacidosis (DKA). Farxiga is currently not approved in T1D.

AstraZeneca will also present an analysis from the CVD-REAL study (Poster #635) which evaluated the efficacy and safety of SGLT2 inhibitors vs. other glucose-lowering medicines. This additional analysis will look at data across a larger number of countries and patients, with a longer duration of follow up than previously evaluated.

Comprehensive new analyses of the safety and efficacy of Bydureon

Results will also be presented from 10 randomised Phase III, 24-to-30-week clinical trials within the DURATION programme (Poster #737), which evaluated the safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonist Bydureon, administered once-weekly either subcutaneously or with an autoinjector, in patients with T2D.

Advancing a potential first-in-class approach to T2D with MEDI0382

From the Company's promising CVRM pipeline, there will be an oral presentation of data from a Phase IIa trial on the observed effects of MEDI0382 on glucose control and weight loss in patients with T2D (Presentation #164). MEDI0382 is an oxyntomodulin-like peptide and potential new medicine designed to simultaneously activate the GLP-1 and glucagon (GLU) receptors, with the goal of achieving glucose control, reduced body weight and increased energy expenditure in patients with T2D.

Details of the key abstracts from AstraZeneca/MedImmune at EASD 2018:

The full list of AstraZeneca/MedImmune scientific data can be accessed on the EASD website here (https://upload.easd.org/download/AM2018/Flipbook/mobile/index.html#p=1). You can also follow us live during EASD 2018 on Twitter (https://twitter.com/AstraZeneca) and LinkedIn (https://www.linkedin.com/company/astrazeneca/).

- ENDS -

NOTES TO EDITORS

About AstraZeneca in Cardiovascular, Renal & Metabolism (CVRM)

Cardiovascular, renal and metabolism together form one of AstraZeneca's main therapy areas and are key growth drivers for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. Our ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Gonzalo Viña UK/Global +44 203 749 5916
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677

Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris Cardiovascular; Metabolism +44 203 749 5711
Nick Stone Respiratory; Renal +44 203 749 5716
Josie Afolabi Other +44 203 749 5631
Craig Marks Finance; Fixed Income +44 7881 615 764
Jennifer Kretzmann Retail Investors +44 203 749 5824
US toll-free +1 866 381 7277